 |
| Original Paper |
| FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins |
 |
| Frédéric Blanchard1,a, Erin Kinzie1, Yanping Wang1, Laurence Duplomb3, Anne Godard3, William A Held1, Bonnie B Asch2 and Heinz Baumann1 |
 |
1Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, New York, NY 14263, USA
2Division of Experimental Pathology, Roswell Park Cancer Institute, Buffalo, New York, NY 14263, USA
3INSERM U463, Institut de Biologie, 9 Quai Moncousu, 44035 Nantes Cedex 01, France
|
Correspondence to: F Blanchard or H Baumann, Roswell Park Cancer Institute, Department of Molecular and Cellular Biology, Buffalo, NY 14263, USA; E-mail: fblan@nantes.inserm.fr or heinz.baumann@roswellpark.org |  |
aCurrent address: INSERM U463, Institut de Biologie, 9 Quai Moncousu, 44035 Nantes Cedex 01, France |
 |
| Abstract |
 | The related members of the interleukin-6 (IL-6) family of cytokines, leukemia inhibitory factor (LIF), oncostatin M (OSM) and IL-6 are inflammatory mediators that control differentiated cell functions as well as proliferation. The cellular responsiveness to these cytokines is largely determined by the expression of the appropriate receptor proteins. The receptor expression profile for each cell type is established during differentiation and is often altered during oncogenic transformation. Since inhibition of histone deacetylases (HDAC) has the potential to re-activate epigenetically silenced genes, we asked whether inhibition of HDAC enhances the expression of IL-6 cytokine receptors and, thus, increase desirable cytokine responses. We demonstrate that treatment with FR901228 (FR), an HDAC inhibitor, increases the responsiveness to LIF in different cell types, including normal fibroblasts, epithelial cells, macrophages and splenocytes, as well as various tumor cell lines. Depending on the cell type, FR treatment also enhances the responsiveness to OSM and IL-6. These effects involve a transcriptional induction of the cytokine receptor subunits LIFRα, OSMRβ, gp130, or the transcription factor STAT3. FR-specific induction of LIFRα occurs independently of de novo protein synthesis and cell proliferation and is mediated in part by the CBP/p300 coactivator. Chromatin immunoprecipitation experiments indicate that the expression of LIFRα and gp130 genes correlates with the level of acetylated histone 3 associated with the receptor promoter regions. The FR-stimulated expression of IL-6-type cytokine receptors in certain tumor cells also provided improved conditions for suppression of cell growth by taking advantage of the growth inhibitory effect of these cytokines. Oncogene (2002) 21, 6264-6277. doi:10.1038/sj.onc.1205777 |
 |
| Keywords |
 | cytokine receptor; inflammatory mediators; signal transduction; gene regulation; cytotoxicity |
|
 |
 |
 |
| Received 5 October 2001; revised 12 June 2002; accepted 18 June 2002 |
 |
| 12 September 2002, Volume 21, Number 41, Pages 6264-6277 |
| Table of contents Previous Abstract Next Full text PDF |
|